Keflex and Organ failure - a phase IV clinical study of FDA data

Summary:

Organ failure is reported as a side effect among people who take Keflex (cephalexin), especially for people who are female, 50-59 old, also take Nexium, and have Gastric ulcer.

The phase IV clinical study analyzes which people have Organ failure when taking Keflex. It is created by eHealthMe based on reports of 14,902 people who have side effects when taking Keflex from the FDA, and is updated regularly.

What is Keflex?

Keflex has active ingredients of cephalexin. It is often used in infection. eHealthMe is studying from 15,844 Keflex users. Check the latest studies of Keflex.

What is Organ failure?

Organ failure is found to be associated with 457 drugs and 646 conditions by eHealthMe. Check the latest studies of Organ failure.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

14,902 people reported to have side effects when taking Keflex.
Among them, 16 people (0.11%) have Organ failure.

Among these 16 people:

What is the gender of people who have Organ failure when taking Keflex? *

female: 84.62 %
male: 15.38 %

What is the age of people who have Organ failure when taking Keflex? *

What are other drugs people take besides Keflex? *

What are other side effects people have besides Organ failure? *

Acute Kidney Failure: 7 people, 43.75%
Kidney Stones: 5 people, 31.25%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 5 people, 31.25%
Gastric Cancer (stomach cancer): 4 people, 25.00%
Fatigue (feeling of tiredness): 4 people, 25.00%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 3 people, 18.75%
Central Nervous System Lesion (an abnormality in tissue of brain or spinal cord): 3 people, 18.75%
Osteomyelitis (infection of bone): 3 people, 18.75%
Haemorrhage (bleeding): 3 people, 18.75%
Feeling Abnormal: 3 people, 18.75%

What are the existing conditions these people have? *

Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 5 people, 31.25%
Pain: 5 people, 31.25%
High Blood Pressure: 5 people, 31.25%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 31.25%
Gastric Ulcer (stomach ulcer): 5 people, 31.25%
Skin Irritation: 3 people, 18.75%
Skin Disorder (skin disease): 3 people, 18.75%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 3 people, 18.75%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 18.75%
Menstruation Irregular: 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Keflex and have Organ failure?

- Check whether Organ failure is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keflex:

Keflex (15,844 reports)

Organ failure treatments and more:

Organ failure (6,816 reports)

Browse all side effects of Keflex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Organ failure:

Organ failure (457 drugs)

Browse all the conditions that are associated with Organ failure:

Organ failure (646 conditions)

Related publications that referenced our studies

Agrawal A, Rao M, Jasdanwala S, Mathur A, Eng M, "Cephalexin Induced Cholestatic Jaundice", Case reports in gastrointestinal medicine, 2014 Aug .
Agrawal A, Rao M, Jasdanwala S, Mathur A, Eng M, "Cephalexin Induced Cholestatic Jaundice", Case reports in gastrointestinal medicine, 2014 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on cephalexin (the active ingredients of Keflex) and Keflex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.